Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AKARI THERAPEUTICS, PLC

(AKTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/26/2021 07/27/2021 07/28/2021 07/29/2021 07/30/2021 Date
1.64(c) 1.59(c) 1.63(c) 1.66(c) 1.62(c) Last
88 730 170 038 81 907 28 563 199 352 Volume
+1.23% -3.05% +2.52% +1.84% -2.41% Change
More quotes
Estimated financial data (e) (USD)
Sales 2019 - - -
Net income 2019 -16,8 M - -
Net cash position 2019 5,73 M - -
P/E ratio 2019 -1,90x
Yield 2019 -
Sales 2020 - - -
Net income 2020 -17,1 M - -
Net cash position 2020 14,1 M - -
P/E ratio 2020 -3,42x
Yield 2020 -
Capitalization 64,2 M 64,2 M -
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 9
Free-Float 99,0%
More Financials
Company
Akari Therapeutics, Plc. a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. The Company’s lead product... 
More about the company
All news about AKARI THERAPEUTICS, PLC
07/30AKARI THERAPEUTICS : Company Presentation – July 2021
PU
07/23European ADRs Move Higher in Friday Trading
MT
07/20AKARI THERAPEUTICS : Securities Purchase Agreement (Form 6-K)
PU
07/15European ADRs Move Lower in Thursday Trading
MT
07/14European ADRs Nudge Higher in Wednesday Trading
MT
07/07AKARI THERAPEUTICS : Enters Deals to Raise $12 Million in Equity Private Placeme..
MT
07/07Akari Therapeutics Announces Private Placement
GL
07/07Akari Therapeutics, Plc announced that it expects to receive $12.318687 milli..
CI
07/02European ADRs Move Lower in Friday Trading
MT
06/29AKARI THERAPEUTICS : Condensed Consolidated Financial Statements (Form 6-K)
PU
06/29Akari Therapeutics, plc Appoints Sanjeev Khindri as New Senior Medical Direct..
CI
06/29AKARI THERAPEUTICS : Reports Wider Dollar Loss in Q1
MT
06/29AKARI THERAPEUTICS : Earnings Flash (AKTX) AKARI THERAPEUTICS Posts Q1 EPS $0.00
MT
06/29Akari Therapeutics Reports Q1 2021 Financial Results and Highlights Recent Cl..
GL
06/29Akari Therapeutics, plc Highlights Recent Clinical Progress
CI
More news
News in other languages on AKARI THERAPEUTICS, PLC

- No features available -

More news
Chart AKARI THERAPEUTICS, PLC
Duration : Period :
Akari Therapeutics, Plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AKARI THERAPEUTICS, PLC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Last Close Price 1,62 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Clive Stuart Richardson CEO, Chief Operating Officer & Director
Torsten Hombeck Chief Financial & Accounting Officer
Raymond Prudo-Chlebosz Executive Chairman
Miles Nunn Chief Scientific Officer
Wynne Weston-Davies Medical Director
Sector and Competitors
1st jan.Capi. (M$)
AKARI THERAPEUTICS, PLC-12.43%64
GILEAD SCIENCES, INC.19.86%85 648
BIONTECH SE302.78%79 303
WUXI APPTEC CO., LTD.33.61%68 112
REGENERON PHARMACEUTICALS20.70%59 505
VERTEX PHARMACEUTICALS-14.71%52 232